Physician profile
David V Espino
NPI 1710094701
$2,605.53
in general payments reported to CMS, 2019-2025
10 companies · $534 in 2025
The $534 reported for 2025 was more than what 82% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $152 · 2021: $245 · 2022: $132 · 2023: $121 · 2024: $593 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.23 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $653.41 | 2019-2025 | Prolia |
| Neurocrine Biosciences, INC. | $513.28 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $513.26 | 2019-2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $211.57 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $124.99 | 2024 | Mounjaro |
| Abbott Laboratories | $124.99 | 2021 | |
| Neurelis, INC. | $120.91 | 2023 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $120.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.91 | 2024 | |
| Novo Nordisk INC | $103.12 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Espino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.